Fetching results...
0 items found

A0522: Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

Assoc. Prof. A. (Andrea) Necchi
Necchi A.1, Shore N.D.2, Gupta S.3, Kulkarni G.4, Dave H.5, Kapadia E.5, Zhao Q.5, Kamat A.6
1Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Dept. of Medical Oncology, Milan, Italy, 2Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, 3Cleveland Clinic Taussig Cancer Center, Dept. of Hematology and Medical Oncology, Cleveland, United States of America, 4University Health Network, Princess Margaret Cancer Centre, University of Toronto, Dept. of Surgical Oncology, Toronto, Canada, 5Merck & Co., Inc., Clinical Research, Rahway, United States of America, 6The University of Texas MD Anderson Cancer Center, Dept. of Urology Oncology, Houston, United States of America
38th Annual EAU Congress
Date – Time - Location
12 March 2023, 10:45 - 12:15, Blue Area, Room 1
Abstract Session 29 - Clinical trials in progress
Non-Disease specific, Trial in progress - Treatment
  • © 2023 European Association of Urology
  • Disclaimer